Real-World Glycemic, Blood Pressure, and Weight Control in Patients with Type 2 Diabetes Mellitus Treated with Canagliflozin - an Electronic Health-Record-Based Study.
CONCLUSIONS: Most patients with inadequate HbA1c and BP levels at baseline achieved respective goals after 3 months of CANA, and the proportions of responders remained stable through 12 months. Weight loss ≥5% was increasingly observed over time.
PMID: 27115475 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Canagliflozin | Clinical Trials | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Electronic Health Records (EHR) | Endocrinology | Health | Invokana | Research | Study | Weight Loss